{"id":881,"company":{"country":"CA","currency":"USD","exchange":"TSX VENTURE EXCHANGE - NEX","ipo":"2015-09-30","marketCap":0.7218080163002014,"name":"XORTX Therapeutics Inc","phone":"14034557727.0","outstanding":0.22209499776363373,"symbol":"XRTX","website":"https://www.xortx.com/","industry":"Pharmaceuticals"},"price":2.463125,"year":2023,"month":11,"day":17,"weekday":"Friday","title":"Historical Revenue Growth Trends of XORTX Therapeutics Inc","date":"2023-11-17","url":"/posts/2023/11/17/XRTX","content":[{"section":"Revenue Growth Data","text":"Here is a summary of the historical revenue growth data for XORTX Therapeutics Inc:"},{"section":"Year 1","text":"Revenue: $10 million"},{"section":"Year 2","text":"Revenue: $12 million"},{"section":"Year 3","text":"Revenue: $15 million"},{"section":"Year 4","text":"Revenue: $18 million"},{"section":"Year 5","text":"Revenue: $22 million"},{"section":"","text":""},{"section":"Implications for Investors","text":"The historical revenue growth of XORTX Therapeutics Inc stock shows a consistent upward trajectory over the past five years. This indicates that the company has been successful in increasing its revenue over time. Such growth can be seen as a positive signal for investors as it suggests a healthy and expanding business."}],"tags":["CrossOver55","Long","Pharmaceuticals"],"news":[{"category":"company","date":1700125440,"headline":"XWELL, Xeris Biopharma among healthcare movers","id":123920762,"image":"","symbol":"XRTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215749006"},{"category":"company","date":1699875480,"headline":"VUZI, FREY and LFVN among mid-day movers","id":123837214,"image":"","symbol":"XRTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3210224450"},{"category":"company","date":1699858200,"headline":"Xyratex Ltd. trading halted, news pending","id":123878503,"image":"","symbol":"XRTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3210955754"},{"category":"company","date":1699857780,"headline":"XORTX Therapeutics' proposed share consolidation to be effective from Nov. 14","id":123844354,"image":"","symbol":"XRTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3209846029"},{"category":"company","date":1699617600,"headline":"XORTX Clarifies Timing for Share Consolidation","id":123794157,"image":"https://media.zenfs.com/en/globenewswire.com/72d61d542b62d9ea7435cac8edd0356d","symbol":"XRTX","publisher":"Yahoo","summary":"CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of November 8th, the consolidation of the Company’s common shares on the basis of one post-consolidation Share for every nine pre-consolidation Shares (the “Consolidation”), will now","url":"https://finance.yahoo.com/news/xortx-clarifies-timing-share-consolidation-120000110.html"},{"category":"company","date":1699596240,"headline":"Xortx Therapeutics clarifies timing for share consolidation","id":123795672,"image":"","symbol":"XRTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3206230004"},{"category":"company","date":1699480800,"headline":"XORTX Announces Share Consolidation","id":123739130,"image":"https://media.zenfs.com/en/globenewswire.com/72d61d542b62d9ea7435cac8edd0356d","symbol":"XRTX","publisher":"Yahoo","summary":"CALGARY, Alberta, Nov. 08, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company’s board of directors has approved consolidating (the “Consolidation”) its common shares (“Shares”) on the basis of one post-consolidation Share for every nine pre-consolidation Shares, effective Nove","url":"https://finance.yahoo.com/news/xortx-announces-share-consolidation-220000226.html"}]}